BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34262146)

  • 1. BRCA-mutant pancreatic ductal adenocarcinoma.
    Lai E; Ziranu P; Spanu D; Dubois M; Pretta A; Tolu S; Camera S; Liscia N; Mariani S; Persano M; Migliari M; Donisi C; Demurtas L; Pusceddu V; Puzzoni M; Scartozzi M
    Br J Cancer; 2021 Nov; 125(10):1321-1332. PubMed ID: 34262146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
    Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis.
    McGarry JL; Creavin B; Kelly ME; Gallagher TK
    J Surg Oncol; 2022 Nov; 126(6):1028-1037. PubMed ID: 35770919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
    J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
    Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
    Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
    Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
    Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
    Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
    J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
    Carnevale J; Ashworth A
    J Clin Oncol; 2015 Oct; 33(28):3080-1. PubMed ID: 25987697
    [No Abstract]   [Full Text] [Related]  

  • 14. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
    Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
    Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
    Roch AM; Schneider J; Carr RA; Lancaster WP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
    J Surg Oncol; 2019 May; 119(6):777-783. PubMed ID: 30636051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
    Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
    Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
    Jordan EJ; Lowery MA; Basturk O; Allen PJ; Yu KH; Tabar V; Beal K; Reidy DL; Yamada Y; Janjigian Y; Abou-Alfa GK; O'Reilly EM
    Clin Colorectal Cancer; 2018 Jun; 17(2):e315-e321. PubMed ID: 29496399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
    Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
    Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.
    Obazee O; Archibugi L; Andriulli A; Soucek P; Małecka-Panas E; Ivanauskas A; Johnson T; Gazouli M; Pausch T; Lawlor RT; Cavestro GM; Milanetto AC; Di Leo M; Pasquali C; Hegyi P; Szentesi A; Radu CE; Gheorghe C; Theodoropoulos GE; Bergmann F; Brenner H; Vodickova L; Katzke V; Campa D; Strobel O; Kaiser J; Pezzilli R; Federici F; Mohelnikova-Duchonova B; Boggi U; Lemstrova R; Johansen JS; Bojesen SE; Chen I; Jensen BV; Capurso G; Pazienza V; Dervenis C; Sperti C; Mambrini A; Hackert T; Kaaks R; Basso D; Talar-Wojnarowska R; Maiello E; Izbicki JR; Cuk K; Saum KU; Cantore M; Kupcinskas J; Palmieri O; Delle Fave G; Landi S; Salvia R; Fogar P; Vashist YK; Scarpa A; Vodicka P; Tjaden C; Iskierka-Jazdzewska E; Canzian F
    Int J Cancer; 2019 Aug; 145(3):686-693. PubMed ID: 30672594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.